Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Roche drug Hemlibra has a good chance to become the first choice of treatment for the patients who are suffering from Hemopilia.Basically, Hemlibra is a humanized monoclonal antibody drug for the treatment of haemophilia which is given through an injection, it was observed that it reduces the bleed dramatically in hemphilia tests.
At the world Federation of Hemophilia’s world congress in Scotland,Roche’s-Genentech unit disclosed the details from the twophases 3 studies on emicizumab. The trails were termed as HEAVEN-3 & HEAVEN-4.
At the world Federation of Hemophilia’s world congress in Scotland,Roche’s-Genentech unit disclosed the details from the twophases 3 studies on emicizumab. The trails were termed as HEAVEN-3 & HEAVEN-4..
It was reported that Hemlibra was able to cut down 96% of the bleeds in Hemophilia. Some comparisons were observed between a patient who didn’t received preventive treatment whereas a patient who received the preventive treatment in the form of clotting factors it reduces them by 68%.
The firm will submit the new data to regulators in the U.S. and Europe for approval.